The Results of a Preclinical Trial Demonstrating the Benefits of Inhaled Pherecydes Pharma Phages in Treating Ventilation-ass...
07 Giugno 2021 - 6:00PM
Business Wire
Regulatory News:
Pherecydes Pharma (FR0011651694 – ALPHE), a biotechnology
company specializing in precision phage therapy to treat resistant
and/or complicated bacterial infections, today announces that the
British Journal of Pharmacology, an international peer-reviewed
medical journal, has published the results of a preclinical trial
undertaken with the phages of Pherecydes Pharma in animal models of
pneumonia due to Pseudomonas aeruginosa.
The Pseudomonas aeruginosa bacterium is a main cause of
Ventilator-Associated Pneumonia (VAP).
The article, entitled “Inhaled
bacteriophage therapy in a porcine model of pneumonia caused by
Pseudomonas aeruginosa during mechanical ventilation”,
details the results obtained with Pherecydes Pharma’s anti-P.
aeruginosa phages during the preclinical study undertaken in
partnership with the Research Center for Respiratory Diseases (UMR
INSERM-University of Tours U1100) and partly funded by the Defense
Innovation Agency (DIA). The phages were administered:
- intranasally in a murine model;
- by nebulization (inhalation) in a porcine model.
The published results, also presented in April at the 6th Annual
Inhalation and Respiratory Drug Delivery Congress, show a major
impact when phages are delivered locally or by nebulization:
- a 100% reduction in the mortality rate in mice with a single
intranasal delivery;
- a 97% reduction in the pulmonary bacterial load in pigs
following two deliveries by inhalation.
Pherecydes Pharma has already carried out a number of
preclinical studies with anti-P. aeruginosa phages in respiratory
tract infection models and obtained extremely positive results. The
Company is planning to make these phages available to hospitals in
France within the framework of an Early Access Program (EAP) in the
second half of 2021 and to initiate Phase I/II clinical development
in respiratory indications within the next two years.
Guy-Charles Fanneau de La Horie, Chairman of the Executive
Board of Pherecydes Pharma, states: “We are very pleased with
this publication in the prestigious British Journal of
Pharmacology. As well as greater recognition among our peers, it
also underlines the growing interest in phage therapy within the
international medical community. Given the solidity of the
preclinical data we have obtained to date, we are confident in the
clinical potential of our anti-P. aeruginosa phages and their
ability to meet the needs of patients with Ventilator-Associated
Pneumonia, a pathology that is seeing a substantial increase
notably as a result of the COVID-19 pandemic”.
About the British Journal of Pharmacology
The British Journal of Pharmacology (BJP) is an international
peer-reviewed medical journal covering all aspects of experimental
pharmacology. It publishes high-quality original research and
authoritative reviews, letters to the editor on topical issues and
comments on the BJP’s publications.
About Pherecydes Pharma
Founded in 2006, Pherecydes Pharma is a biotechnology company
that develops treatments against resistant bacterial infections,
responsible for many serious infections. The Company has developed
an innovative approach, precision phage therapy, based on the use
of phages, natural bacteria-killing viruses. Pherecydes Pharma is
developing a portfolio of phages targeting 3 of the most resistant
and dangerous bacteria, which alone account for more than two
thirds of hospital-acquired resistant infections: Staphylococcus
aureus, Escherichia coli and Pseudomonas aeruginosa. The concept of
precision phage therapy has been successfully applied in 26
patients in the context of compassionate use, under the supervision
of the French National Agency for the Safety of Medicines (ANSM).
Headquartered in Nantes, Pherecydes Pharma has a team of around
twenty experts from the pharmaceutical industry, biotechnology
sector and academic research.
For more information, www.pherecydes-pharma.com
Disclaimer
This press release contains non-factual elements, including, but
not limited to, certain statements regarding future results and
other future events. These statements are based on the current
vision and assumptions of the management of the Company. They
incorporate known and unknown risks and uncertainties that could
result in significant differences in results, profitability and
expected events. In addition, Pherecydes Pharma, its shareholders
and its affiliates, directors, officers, counsels and employees
have not verified the accuracy of, and make no representations or
warranties about, statistical information or forecast information
contained within this news release and that originates or is
derived from third party sources or industry publications; these
statistical data and forecast information are only used in this
press release for information purposes. Finally, this press release
may be drafted in French and in English. In the event of
differences between the two texts, the French version will
prevail.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210607005526/en/
Pherecydes Pharma Philippe Rousseau CFO
investors@pherecydes-pharma.com
NewCap Dusan Oresansky Investor Relations
pherecydes@newcap.eu T.: +33 1 44 71 94 92
NewCap Nicolas Merigeau Media Relations
pherecydes@newcap.eu T.:
+33 1 44 71 94 98